ProMIS Neurosciences Inc. (PMN): Results of Operations and Financial Condition
ProMIS Neurosciences Inc. (PMN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights • Announced positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Company's Phase 1b trial of PMN310 in patients with early Alzhe
How this was made
The 30-second read
Why it matters
The key tradable elements are (1) interim safety showing no ARIA-E across 136 evaluable participants including APOE4 homozygotes, (2) directionally favorable biomarker declines (plasma pTau217, CSF MTBR-tau243) in a blinded pooled analysis, and (3) updated cash position and runway through 2027, extending the time horizon to the unblinded 12-month topline readout expected in Q1 2027.
Market read
Traders can reprice PMN’s clinical-risk profile based on interim ARIA-E safety and biomarker directionality, while using the stated Q1 2027 unblinded topline timing as the next decision point.
What to watch
The article does not provide unblinded efficacy or cognitive outcomes yet, and it pools active and placebo in the biomarker analysis, which can dilute interpretability.
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
The company reported favorable blinded interim safety and biomarker observations for PMN310 and cash runway through 2027, while quarterly net loss increased from the prior-year period and the pivotal readout remains pending.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expense, three months ended June 30, 2026GAAP | $9,521,793 | – | – |
| General and administrative expense, three months ended June 30, 2026GAAP | $2,744,606 | – | – |
| Total operating expenses, three months ended June 30, 2026GAAP | $12,266,399 | – | – |
| Loss from operations, three months ended June 30, 2026GAAP | (12,266,399) | – | – |
| Other income, three months ended June 30, 2026GAAP | 536,743 | – | – |
| Net loss, three months ended June 30, 2026GAAP | $(11,729,656) | – | – |
| Net loss per share, basic and diluted, three months ended June 30, 2026GAAP | $(1.28) | – | – |
| Weighted-average outstanding Common Shares, basic and diluted, three months ended June 30, 2026other | 9,142,366 | – | – |
| Research and development expense, six months ended June 30, 2026GAAP | $16,492,799 | – | – |
| General and administrative expense, six months ended June 30, 2026GAAP | $4,418,497 | – | – |
| Total operating expenses, six months ended June 30, 2026GAAP | $20,911,296 | – | – |
| Loss from operations, six months ended June 30, 2026GAAP | (20,911,296) | – | – |
| Other income, six months ended June 30, 2026GAAP | 937,267 | – | – |
| Net loss, six months ended June 30, 2026GAAP | $(19,974,029) | – | – |
| Net loss per share, basic and diluted, six months ended June 30, 2026GAAP | $(2.54) | – | – |
| Weighted-average outstanding Common Shares, basic and diluted, six months ended June 30, 2026other | 7,874,562 | – | – |
| Cash, June 30, 2026other | $53,429,280 | – | – |
| Short-term investments, June 30, 2026other | 33,753 | – | – |
| Prepaid expenses and other current assets, June 30, 2026other | 3,230,900 | – | – |
| Total current assets, June 30, 2026other | $56,693,933 | – | – |
| Total assets, June 30, 2026other | $56,693,933 | – | – |
| Accounts payable, June 30, 2026other | $1,793,475 | – | – |
| Accrued liabilities, June 30, 2026other | 5,424,269 | – | – |
| Total current liabilities, June 30, 2026other | $7,217,744 | – | – |
| Share-based compensation liability, June 30, 2026other | 77,255 | – | – |
| Total liabilities, June 30, 2026other | $7,294,999 | – | – |
| Additional paid-in capital, June 30, 2026other | 200,150,367 | – | – |
| Accumulated other comprehensive loss, June 30, 2026other | (371,184) | – | – |
| Accumulated deficit, June 30, 2026other | (150,380,249) | – | – |
| Total shareholders’ equity (deficit), June 30, 2026other | $49,398,934 | – | – |
| Total liabilities and shareholders’ equity (deficit), June 30, 2026other | $56,693,933 | – | – |
Through 2027 outlook
- NoteBased on the current operating plan, existing cash resources are expected to fund planned operations through 2027.
- NoteThe Company expects all patients to complete 12-month dosing by the fourth quarter of 2026.
- NoteThe Company expects to report unblinded 12-month topline data, including the full safety dataset, an expanded biomarker panel, and clinical cognitive outcome measures, in the first quarter of 2027.
What drove it
- The PRECISE-AD interim analysis reported no cases of ARIA-E across all 136 safety-evaluable participants and APOE genotypes.
- Total ARIA incidence was 4.4%, with all cases mild and asymptomatic and consisting only of ARIA-H.
- In the blinded pooled analysis, plasma pTau217 declined approximately 15% from baseline through Day 169 and CSF MTBR-tau243 declined approximately 13.3%.
- The January 2026 private placement generated $70.1 million in net proceeds.
Concerns
- PRECISE-AD remains blinded and ongoing, and the interim biomarker analysis pooled active- and placebo-treated patients.
- The filing states that early or interim results may not be indicative of final or top-line results.
- Quarterly net loss was $(11,729,656), compared to $(10,117,029) for the same period in 2025.
- The Company expects continued losses.
What to watch
- Completion of 12-month dosing for all PRECISE-AD patients by the fourth quarter of 2026.
- Unblinded 12-month PRECISE-AD topline data in the first quarter of 2027, including safety, biomarkers, and clinical cognitive outcome measures.
- The full safety dataset, including ARIA findings across APOE genotypes.
- Progress of PMN267 and PMN442 through IND-enabling studies.
Balance sheet and cash flow
- As of June 30, 2026, the Company’s cash and short-term investments were $53.4 million, compared to $6.1 million as of December 31, 2025.
- The increase primarily reflects $70.1 million in net proceeds received in January 2026 from a private placement financing.
- Cash was $53,429,280 as of June 30, 2026, compared to $6,116,556 as of December 31, 2025.
- Total current liabilities were $7,217,744 as of June 30, 2026, compared to $10,411,831 as of December 31, 2025.
Analysis
ProMIS remains a development-stage company without reported revenue. The quarter’s central development was the blinded six-month interim PRECISE-AD update for PMN310. The company reported no ARIA-E cases among 136 safety-evaluable participants across APOE genotypes, while total ARIA incidence was 4.4%, all mild and asymptomatic ARIA-H. Blinded pooled biomarker observations showed approximately 15% decline in plasma pTau217 through Day 169 and approximately 13.3% decline in CSF MTBR-tau243.
The clinical dataset remains preliminary because the study is blinded and the biomarker analysis pooled active- and placebo-treated patients under the ongoing 3-to-1 randomization. The company expects all patients to complete 12-month dosing by the fourth quarter of 2026. The key clinical catalyst is unblinded 12-month topline PRECISE-AD data in the first quarter of 2027, which is expected to include cognitive outcomes, the full safety dataset, and an expanded biomarker panel.
Financially, research and development expense was $9,521,793 and general and administrative expense was $2,744,606 for the quarter. Total operating expenses were $12,266,399, compared with $10,184,661 for the same period in 2025. Net loss was $(11,729,656), compared with $(10,117,029), while net loss per share improved to $(1.28) from $(7.26), which the company attributed to higher weighted-average shares outstanding after the January 2026 financing.
Liquidity is the principal financial support for the clinical timetable. Cash and short-term investments were $53.4 million as of June 30, 2026, compared to $6.1 million as of December 31, 2025, primarily reflecting $70.1 million in net proceeds from the January 2026 private placement. Management expects existing cash resources to fund planned operations through 2027, beyond the anticipated first-quarter 2027 readout. There were no reported capital returns, debt balances, operating cash flow, or free cash flow in the filing.
Pipeline activity outside PMN310 continued, with PMN267 progressing through IND-enabling studies and PMN442 advancing toward IND-enabling studies. The near-term investor focus is therefore concentrated on PRECISE-AD completion and the transition from blinded interim observations to unblinded safety, biomarker, and cognitive data. The filing explicitly notes that early or interim results may not be indicative of final or top-line results.
Management, verbatim
The second quarter of 2026 was a pivotal period for ProMIS, as we continued to advance PRECISE-AD while maintaining a strong financial position.
Neil Warma, President and Chief Executive Officer of ProMIS Neurosciences
We ended the quarter with $53.4 million in cash and short-term investments, providing runway through 2027, beyond our next major anticipated catalyst.
Neil Warma, President and Chief Executive Officer of ProMIS Neurosciences
We look forward to the 12-month unblinded topline results from PRECISE-AD, expected in the first quarter of 2027, which will include cognitive outcomes, and we believe will represent an important next step in evaluating PMN310’s potential for patients with early AD.
Neil Warma, President and Chief Executive Officer of ProMIS Neurosciences
Not in the filing
stated, not guessed- Revenue
- Segment revenue and segment comparisons
- Gross profit
- Gross margin
- GAAP operating income
- GAAP net income
- Non-GAAP revenue, gross margin, operating income, net income, and earnings per share
- Operating cash flow
- Free cash flow
- Debt balance
- Capital returns, including share repurchases and dividends
- Tax rate
- Prior-quarter operating results and prior-quarter comparisons
- Financial guidance for revenue, gross margin, operating expenses, and tax rate
- Prior-quarter outlook for comparison
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC 8-K with Exhibit 99.1 covering ProMIS’s Q2 2026 financials and interim blinded PRECISE-AD (PMN310) safety and biomarker updates.
Ticker impact
ProMIS reported PRECISE-AD Phase 1b interim data, including zero ARIA-E cases and biomarker declines, plus $53.4M cash runway through 2027.
Likely positive bias for PMN into the next catalyst, with volatility around the eventual unblinding and cognitive outcomes.
The filing is a primary disclosure of interim blinded safety and biomarker trends, and it explicitly frames the next major decision point as Q1 2027 unblinded topline data.
Market effects
Adds incremental evidence for amyloid-beta oligomer targeting with potentially lower ARIA risk, relevant to Alzheimer’s antibody safety expectations.
Limited direct regional spillover; primarily impacts US biotech sentiment and clinical-risk pricing.
Moderate, as Alzheimer’s trial safety signals can influence global peer read-across and investor risk appetite.
Counterpoint
Blinded interim biomarker movement may not translate into cognitive benefit, and the ARIA-E zero result could still change with longer exposure or unblinding.
Key entities
- companyProMIS Neurosciences Inc.
Clinical-stage biotech developing antibody therapeutics for neurodegenerative diseases; subject of the 8-K.
- programPMN310
Phase 1b antibody therapeutic in early Alzheimer’s disease under the PRECISE-AD trial.
- clinical_trialPRECISE-AD
Randomized, double-blind, placebo-controlled Phase 1b trial in mild cognitive impairment due to early AD.
